Cyclopentenylcytosine does not enhance cisplatin-induced radiosensitization in human lung tumour cells

Rodermond,Hans M.; ten Cate,Rosemarie; Haveman,Jaap; van Kuilenburg,André; Medema,Jan P.; van Bree,Chris; Franken,Nicolaas A.P.

doi:10.3892/ol_00000095

Cyclopentenylcytosine does not enhance cisplatin-induced radiosensitization in human lung tumour cells

Authors:
- Hans M. Rodermond
- Rosemarie ten Cate
- Jaap Haveman
- André van Kuilenburg
- Jan P. Medema
- Chris van Bree
- Nicolaas A.P. Franken
View Affiliations

Affiliations: Laboratory for Experimental Oncology and Radiobiology (LEXOR), Department of Radiation Oncology, Center for Experimental Molecular Medicine, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
Published online on: May 1, 2010 https://doi.org/10.3892/ol_00000095
Pages: 537-540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The search for agents that enhance the effect of ionizing radiation has been an object of study for decades. In this study, the sensitizing properties of cyclopentenylcytosine (CPEC) on radiation and cisplatin-induced radiosensitization in human squamous lung carcinoma cells were investigated. Human lung tumour SW-1573 cells (SWp, parental; SWg, gemcitabine-resistant) were incubated with CPEC and cisplatin and subsequently irradiated with different doses of γ-rays. Clonogenic survival was determined to measure the effectiveness of the treatments. CPEC (1 or 2 µM) treatment for 4 h decreased the plating efficiency to 75 and 50% in SWp and SWg cells, respectively. In the SWg cells, 0.1 and 1 µM CPEC for 4 h enhanced the cell killing effect of cisplatin. However, an increase was not noted in the SWp cells. Due to the moderate toxicity of 1 µM for 4 h, this CPEC dose was used in the radiosensitization experiments. However, CPEC neither radiosensitized the lung tumour cells nor enhanced the radiosensitizing effect of cisplatin. A 2-h incubation with 4 µM cisplatin also decreased the plating efficiency to 75-80% in the two cell lines. Using this cisplatin dose, radiosensitization was obtained in the two cell lines. Although cisplatin treatment clearly radiosensitized the lung tumour cells, CPEC treatment did not. Cisplatin-induced radiosensitization was also not enhanced by CPEC.

View Figures

View References

1	Gharehbaghi K, Zhen W, Fritzer-Szekeres M, Szekeres T and Jayaram HN: Studies on the antitumour activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo. Life Sci. 64:103–112. 1999. View Article : Google Scholar : PubMed/NCBI
2	Gharehbaghi K, Szekeres T, Yalowitz JA, Fritzer-Szekeres M, Pommier YG and Jayaram HN: Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. Life Sci. 68:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
3	Van Bree C, Rodermond HM, Leen R, Medema J and van Kuilenburg AB: Cyclopentenylcytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells. Br J Cancer. 98:1226–1233. 2008.PubMed/NCBI
4	Van Bree C, Barten-van Rijbroek AD, Leen R, Rodermond HM, van Kuilenburg AB and Kal HB: Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models. Int J Oncol. 34:813–819. 2009.PubMed/NCBI
5	Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim HY, Marquez VE and Johns DG: Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J Biol Chem. 264:713–718. 1989.PubMed/NCBI
6	Bierau J, van Gennip AH, Leen R, Meinsma R, Caron HN and van Kuilenburg AB: Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. Cancer Chemother Pharmacol. 57:105–113. 2006. View Article : Google Scholar : PubMed/NCBI
7	Crul M, van Waardenburg RC, Beijnen JH and Schellens JH: DNA-based drug interactions of cisplatin. Cancer Treat Rev. 28:291–303. 2002. View Article : Google Scholar : PubMed/NCBI
8	Myint WK, Ng C and Raaphorst GP: Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol. 78:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
9	Lawrence TS, Blackstock AW and McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Sem Radiat Oncol. 13:13–21. 2003. View Article : Google Scholar : PubMed/NCBI
10	Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
11	Bergs JW, Haveman J, ten Cate R, Medema JP, Franken NA and van Bree C: Effect of 41ºC and 43ºC on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin. Oncol Rep. 18:219–226. 2007.
12	Haveman J, Castro Kreder N, Rodermond HM, van Bree C, Franken NA, Stalpers LJ, Zdzienicka MZ and Peters GJ: Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep. 12:187–192. 2004.PubMed/NCBI
13	Van Bree C, Castro Kreder N, Loves WJ, Franken NA, Peters GJ and Haveman J: Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumour cell lines. Int J Radiat Oncol Biol Phys. 54:237–244. 2002.PubMed/NCBI
14	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
15	Barendsen GW, van Bree C and Franken NA: Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: Implications for combined tumour treatments (review). Int J Oncol. 19:247–256. 2001.
16	Barendsen GW: Parameters of linear-quadratic radiation dose-effect relationships: dependence on LET and mechanisms of reproductive cell death. Int J Radiat Biol. 71:649–655. 1997. View Article : Google Scholar : PubMed/NCBI
17	Franken NA, van Bree C, Veltmaat MA, Rodermond HM, Haveman J and Barendsen GW: Radiosensitization by bromodeoxyuridine and hyperthermia: analysis of linear and quadratic parameters of radiation survival curves of two human tumour cell lines. J Radiat Res. 42:179–190. 2001. View Article : Google Scholar : PubMed/NCBI
18	Franken NA, van Bree C, Kipp JBA and Barendsen GW: Modification of potentially lethal damage in irradiated Chinese hamster V79 cells after incorporation of halogenated pyrimidines. Int J Radiat Biol. 72:101–109. 1997. View Article : Google Scholar : PubMed/NCBI
19	Franken NA, van Bree C, Streefkerk JO, Kuper IMJA, Rodermond HM, Kipp JBA, Haveman J and Barendsen GW: Radiosensitization by iodo-deoxyuridine in cultured SW-1573 human lung tumour cells: Effects on α and β of the linear-quadratic model. Oncol Rep. 4:1073–1076. 1997.PubMed/NCBI
20	Akudugu JM and Slabbert JP: Modulation of radiosensitivity in Chinese hamster lung fibroblasts by cisplatin. Can J Physiol Pharmacol. 86:257–263. 2008. View Article : Google Scholar : PubMed/NCBI
21	Bergs JW, Franken NA, ten Cate R, van Bree C and Haveman J: Effects of cisplatin and gamma-irradiation on cell survival, the induction of chromosomal aberrations and apoptosis in SW-1573 cells. Mutat Res. 594:148–154. 2006. View Article : Google Scholar : PubMed/NCBI
22	Wilkins DE, Heller DP and Raaphorst GP: Inhibition of potentially lethal damage recovery by cisplatin in a brain tumour cell line. Anticancer Res. 13:2137–2142. 1993.PubMed/NCBI
23	Begg AC, van Der Kolk PJ, Dewit L and Bartelink H: Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol. 50:871–884. 1986. View Article : Google Scholar : PubMed/NCBI